Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PEM+ Clear all
Terminated Not applicable Interventional Results available

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

NCT01012440
View directory record Official record
Conditions
Breast Cancer
Interventions
PEM Flex Solo II PET Scanner, MRI scan
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Results available

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT05216835
View directory record Official record
Conditions
Relapsed or Refractory Classical Hodgkin Lymphoma
Interventions
Sabestomig (AZD7789)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 101 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Duarte, California • Miami, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 1 Interventional Results available

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

NCT03384316
View directory record Official record
Conditions
Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer, Colon Cancer
Interventions
ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 20, 2026, 2:02 AM EDT
Recruiting Not applicable Interventional

Simulation Trial of Telemedical Support for Paramedics

NCT06441760
View directory record Official record
Conditions
Emergencies, Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus
Interventions
Video teleconsultation, Audio support
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Flavored, Carbonated Drinks on Salivary Flow, Salivary Composition, and Taste Perceptions

NCT06933290
View directory record Official record
Conditions
Taste Perception, Saliva Production
Interventions
Beverage
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Not applicable Interventional

Implementation of Electronic Shared Decision-Making Support for Early Intervention

NCT04562038
View directory record Official record
Conditions
Child Development Disorder, Development Delay
Interventions
Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
3 Months to 36 Months
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

Effect of Stellate Ganglion Block on ME/CFS

NCT05664711
View directory record Official record
Conditions
Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome, Chronic Fatigue Disorder, Chronic Fatigue and Immune Dysfunction Syndrome, Myalgic Encephalomyelitis, Postviral Fatigue Syndrome, Systemic Exertion Intolerance Disease, Infectious Mononucleosis-Like Syndrome, Chronic, Chronic Fatigue-Fibromyalgia Syndrome
Interventions
Bupivacaine Injection
Drug
Lead sponsor
Neuroversion, Inc.
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Early Phase 1 Interventional

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

NCT01864083
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Tomography (PET), Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC), Positron emission mammography (PEM) When available, MR
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 20, 2026, 2:02 AM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 20, 2026, 2:02 AM EDT
Withdrawn No phase listed Observational

Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer

NCT00934401
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 100 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors

NCT01613430
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Cervical Cancer
Interventions
Coach Training (COACH), Printed Educational Materials (PEM)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
50 Years to 74 Years
Enrollment
1,106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
View directory record Official record
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 20, 2026, 2:02 AM EDT
Withdrawn Phase 2 Interventional

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

NCT03574649
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Nab-paclitaxel, Cisplatin, 5Fluorouracil, Cyclophosphamide, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6301, Aldoxorubicin, Avelumab, ALT-803, haNK, Docetaxel, carboplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 20, 2026, 2:02 AM EDT
Withdrawn Phase 2 Interventional

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

NCT03554109
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 2 Interventional

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170
View directory record Official record
Conditions
Esophageal Reflux
Interventions
Rabeprazole
Drug
Lead sponsor
University of Kansas
Other
Eligibility
19 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 20, 2026, 2:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucin Levels in Dry Eye and Normal Populations

NCT05911555
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 20, 2026, 2:02 AM EDT
Recruiting Phase 1 Interventional

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

NCT07166601
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
M0324, Pembrolizumab, mFOLFIRINOX
Biological · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 20, 2026, 2:02 AM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 20, 2026, 2:02 AM EDT
Terminated Not applicable Interventional Results available

Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

NCT01249157
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 20, 2026, 2:02 AM EDT
Completed No phase listed Observational

Cosmetic Outcomes and Patient Satisfaction After Facial Laceration Repair in the Emergency Department

NCT01514084
View directory record Official record
Conditions
Facial Lacerations
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Twin Cities, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 2 Interventional Results available

Ovarian Cancer Vaccine for Patients in Remission

NCT01068509
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
13
States / cities
Greenbrae, California • La Jolla, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 20, 2026, 2:02 AM EDT
Not listed Phase 4 Interventional

Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer

NCT00484614
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron Emission Mammography, Magnetic Resonance Imaging
Procedure
Lead sponsor
Naviscan PET Systems
Industry
Eligibility
25 Years and older · Female only
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Sep 20, 2026, 2:02 AM EDT
Completed Phase 3 Interventional Results available

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

NCT01197833
View directory record Official record
Conditions
Great Saphenous Vein Incompetence, Visible Varicosities
Interventions
endovenous ablation+polidocanol injectable microfoam 0.125%, Endovenous ablation+polidocanol injectable microfoam 1.0%, Endovenous ablation+polidocanol injectable foam 2.0%
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Bradenton, Florida • Oak Brook, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 20, 2026, 2:02 AM EDT
Terminated Phase 1 Interventional

FBnTP Imaging of Breast Cancer

NCT02204462
View directory record Official record
Conditions
Breast Cancer
Interventions
FBnTP
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
26 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 20, 2026, 2:02 AM EDT